Life Sciences Legal Insights, published by Fenwick & West LLP, focuses on legal developments and business trends affecting the life sciences sector. The blog covers topics such as digital health innovations, pharmaceutical and biotech IPOs, regulatory and compliance issues, intellectual property matters including patent litigation, and the impact of emerging technologies on healthcare delivery. It also addresses market dynamics like venture capital funding, SPAC transactions, and mergers and acquisitions within life sciences. The content includes analysis of legal challenges faced by startups and established companies, as well as strategic considerations for growth and exit opportunities in the life sciences industry.
Fenwick corporate lawyer Julia Forbess discussed biotech investment and financing trends with the BIO Buzz Center at the 2017 BIO Investor Forum.
“For 2018, we’re still expecting to see investment in core areas—oncology, orphan drugs and neurology. One thing…
At a symposium and webinar presented by Fenwick & West and Mewburn Ellis, we asked U.S. Patent and Trademark Office and European Patent Office examiners to provide perspective on the preparation and prosecution of patent applications in the areas of…
Fenwick’s Sixth Annual Digital Health Investor Summit started on an upbeat note with Rock Health’s Megan Zweig sharing the venture fund’s mid-year funding report. After the uncertainty brought by the 2016 presidential election and the political drama surrounding the…
It looks like the FDA is moving forward—and swiftly—with the digital health plan articulated in FDA Commissioner Scott Gottlieb’s June blog post, previously outlined in this post. Closely tracking the commissioner’s post, the Center for Devices & Radiological Health…
The FBI arrested Shkreli in December 2015, and the U.S. Attorney’s Office for the Eastern District of New York charged him with securities fraud, securities fraud conspiracy and wire fraud conspiracy for interrelated schemes “to ensnare investors through a…
The digital health sector is beginning to mature and investors are pouring more money into more deals, reports Rock Health in its survey of digital health investment in the first half of 2017. And, we might add, into bigger deals.…
Subject matter eligibility in the United States has recently become a key issue in patent law that has impacted a wide range of technologies in both the life sciences and technology industries. Despite the increased importance of eligibility, there remains…
Last September, we noted that payers and providers were expected to become increasingly active digital health strategic investors given their challenges to improve margins and outcomes. While there were only three investments by payer/providers in the second half of 2016,…
On Friday, January 13, the Supreme Court granted certiorari in Amgen v. Sandoz (Nos. 15-1039 & 15-1195). The Supreme Court originally deferred its decision on the parties’ certiorari petitions in order to consider the Solicitor General’s views. See prior post…
If your work involves life sciences dealmaking, you know it’s the time of year to start firming up your plans for the week of the J.P. Morgan Healthcare Conference. In the last 10 years, the second week of January in San…
